BR0103888A - Combinações farmacêuticas para o tratamento de derrames e lesões cerebrais traumáticas - Google Patents

Combinações farmacêuticas para o tratamento de derrames e lesões cerebrais traumáticas

Info

Publication number
BR0103888A
BR0103888A BR0103888-5A BR0103888A BR0103888A BR 0103888 A BR0103888 A BR 0103888A BR 0103888 A BR0103888 A BR 0103888A BR 0103888 A BR0103888 A BR 0103888A
Authority
BR
Brazil
Prior art keywords
treatment
antagonist
traumatic brain
receptor
pharmaceutical combinations
Prior art date
Application number
BR0103888-5A
Other languages
English (en)
Inventor
Bertrand Leo Chenard
Frank Samuel Menniti
Mario David Saltarelli
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0103888A publication Critical patent/BR0103888A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMBINAçõES FARMACêUTICAS PARA O TRATAMENTO DE DERRAMES E LESõES CEREBRAIS TRAUMáTICAS". Esta invenção relaciona-se com métodos para o tratamento de lesões cerebrais traumáticas ( TBI ) ou derrame isquémico ou hipóxico, compreendendo a administração a um doente necessitado desse tratamento de um antagonista de receptores de N-metil-D-aspartato ( NMDA ) seletivo para o subtipo NR2B em combinação com: ( a ) um factor de inibição de neutrófilos ( NIF ); ( b ) um antagonista de canais de sódio; ( c ) um inibidor de óxido nítrico sintetase ( NOS ); ( d ) um antagonista de sítios de glicina; ( e ) um desbloqueador de canais de potássio; ( f ) um antagonista de receptores de AMPA/kainato; ( g ) um antagonista de canais de cálcio; ( h ) um modulador de receptores de GABA-A ( e.g., um agonista de receptores de GABA-A ); ou ( i ) um agente anti-inflamatório.
BR0103888-5A 2000-09-06 2001-09-05 Combinações farmacêuticas para o tratamento de derrames e lesões cerebrais traumáticas BR0103888A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23094400P 2000-09-06 2000-09-06

Publications (1)

Publication Number Publication Date
BR0103888A true BR0103888A (pt) 2002-06-04

Family

ID=22867173

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0103888-5A BR0103888A (pt) 2000-09-06 2001-09-05 Combinações farmacêuticas para o tratamento de derrames e lesões cerebrais traumáticas

Country Status (6)

Country Link
US (1) US6667317B2 (pt)
EP (1) EP1186303A3 (pt)
JP (1) JP2002322095A (pt)
BR (1) BR0103888A (pt)
CA (1) CA2356557A1 (pt)
MX (1) MXPA01008994A (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
UA79248C2 (en) * 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2493883C (en) * 2002-07-12 2011-08-30 Japan Science And Technology Agency Drugs for improving the prognosis of brain injury and a method of screening the same
US9254279B2 (en) * 2004-05-12 2016-02-09 Baxter International Inc. Nitric oxide scavengers
HU227000B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013067770A1 (en) * 2011-11-10 2013-05-16 Jinhui Chen Compositions and methods for treating traumatic brain injury
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
WO2014138460A1 (en) 2013-03-07 2014-09-12 Northwestern University 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
WO2016073623A2 (en) 2014-11-04 2016-05-12 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック， エルエルシー Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2023133230A1 (en) * 2022-01-08 2023-07-13 Sohn Joanna Monoacetyldiglycerides (plag) as a mitigating agent for traumatic brain injury and ischemia-reperfusion injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
CA2135390A1 (en) * 1992-05-11 1993-11-25 Matthew Moyle Novel neutrophil inhibitors
US6046213A (en) * 1994-08-18 2000-04-04 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
RO120134B1 (ro) * 1995-08-11 2005-09-30 Pfizer Inc. Trihidrat de metansulfonat de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol şi compoziţie farmaceutică
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9804886D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination

Also Published As

Publication number Publication date
US20020045656A1 (en) 2002-04-18
US6667317B2 (en) 2003-12-23
EP1186303A2 (en) 2002-03-13
MXPA01008994A (es) 2004-11-10
EP1186303A3 (en) 2003-12-10
JP2002322095A (ja) 2002-11-08
CA2356557A1 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
BR0103888A (pt) Combinações farmacêuticas para o tratamento de derrames e lesões cerebrais traumáticas
TWI255719B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
BR9914251A (pt) Formulações orais de liberação sustentada
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0208411B8 (pt) composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
BR0014440A (pt) Formulações de liberação controlada oral
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.